For the quarter ending 2025-09-30, ABEO had -$80,651K decrease in cash & cash equivalents over the period. -$23,707K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -5,161 | 96,804 |
| Depreciation and amortization | 608 | 1,078 |
| Gain on disposal of property and equipment | - | 0 |
| Stock-based compensation expense | 2,689 | 5,531 |
| Change in fair value of warrant and derivative liabilities | -2,760 | -1,857 |
| Accretion and interest on short-term investments | 88 | -290 |
| Amortization of right-of-use lease assets | 280 | 505 |
| Non-cash interest | 270 | 598 |
| Gain from sale of priority review voucher | 0 | 152,366 |
| Inventory | 2,164 | 2,686 |
| Other receivables | -14 | -22 |
| Prepaid expenses and other current assets | 119 | 947 |
| Other assets | 203 | 242 |
| Accounts payable and accrued expenses | 1,001 | 1,301 |
| Accrued taxes | -15,173 | 15,512 |
| Lease liabilities | -381 | -667 |
| Other current liabilities | 0 | -62 |
| Net cash used in operating activities | -21,187 | -37,186 |
| Proceeds from disposal of property and equipment | - | 0 |
| Proceeds from sale of priority review voucher, net of transaction costs of 2.6 million | 0 | 152,366 |
| Capital expenditures | 2,520 | 4,302 |
| Purchases of short-term investments | 100,351 | 68,499 |
| Proceeds from maturities of short-term investments | 38,244 | 80,536 |
| Net cash provided by (used in) investing activities | -64,627 | 160,101 |
| Proceeds from underwritten sales of common stock, net of issuance costs | - | 0 |
| Proceeds from issuance of long-term debt | - | 0 |
| Proceeds from atm sales of common stock, net of issuance costs | 0 | 17,300 |
| Payment of debt issuance costs | - | 0 |
| Payments related to net settlement of restricted share awards | 0 | -37 |
| Proceeds from exercise of warrants | 5,163 | - |
| Net cash provided by financing activities | 5,163 | 17,263 |
| Net increase in cash, cash equivalents and restricted cash | -80,651 | 140,178 |
| Cash and cash equivalents at beginning of period | 23,695 | - |
| Cash and cash equivalents at end of period | 83,222 | - |
ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)